Xencor (XNCR) – Globe Newswire
-
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
-
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
-
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
-
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
-
Lancement de Zenas BioPharma, société biopharmaceutique transfrontalière qui innove dans le développement et la fourniture de traitements immunitaires
-
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
-
Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
-
Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Back to XNCR Stock Lookup
